Vendor dossier · Shanghai
Shanghai Sigma-Audley New Material Technology Co., Ltd.
A 2018 Shanghai entrant with unusually complete documentation and an unusually narrow catalogue.
Journal grade · ranked 5 of 20
864 reader reports
on the record
SSA does fewer things than most of the companies in this directory, and appears to do them more carefully. The catalogue we were quoted from in April 2026 ran to fourteen molecules. Every certificate we have received has carried a method and a batch number that matched the vial. The company answers questions in writing, in detail, and has twice corrected its own certificate when we queried an integration.
Storefront The company sells directly at shanghaisigmaaudley.com. Visit SSA → — a labelled, nofollowed link the Journal is paid nothing for. Read the record before you use it.
The record
Nine independent purity determinations, mean 98.1%, range 96.8–99.2%. The 96.8% result — a tirzepatide lot from July 2025 — was disclosed by the vendor before we tested it: their own certificate reported 96.9% against a 97.0% specification, and they flagged the near-miss in the order correspondence rather than shipping it silently. That single act moved this dossier's assessment more than any purity figure in it.
Peptide content is where SSA is weakest, and to its credit it does not pretend otherwise. Content by nitrogen determination is not offered as standard and was quoted to us as an additional cost with a four-week turnaround. Two of our nine samples were tested for content independently; both came in at 92–94% of label, which is within the range we see across the whole directory but below the vendor's own literature.
On the corporate side this is the most legible entity in the set. The registered name, the address and the 2018 incorporation are consistent across everything we have been shown, and the person who signs the correspondence has done so under the same name for two years.
Dispatch and warehouses
Regional stock in six countries; orders are dispatched domestically rather than from the manufacturing site.
- Netherlands (Rotterdam) — European Union, 2-4 days
- Germany (Hamburg) — Germany, Austria, Switzerland, 2-4 days
- United Kingdom (London) — United Kingdom & Ireland, 2-3 days
- United States (California) — United States, 2-4 days
- Canada (Toronto) — Canada, 3-5 days
- Australia (Melbourne) — Australia & New Zealand, 3-5 days
What we verified
- Nine independent purity determinations, mean 98.1% (range 96.8–99.2%).
- Self-disclosure of a near-specification result before shipping, on one occasion, documented in the order correspondence.
- Two certificate corrections issued on our query, both within four working days.
- Registered entity name, address and 2018 incorporation consistent with all documents supplied.
What we could not verify
- Peptide content as a routine release test. Quoted as an extra; two of our own determinations returned 92–94% of label.
- Sterility and endotoxin. Not offered, not claimed.
- Whether the narrow catalogue reflects deliberate focus or limited synthesis capacity — we have asked and been told the former.
- The identity of the fill-finish operation.
Documented testing record
Every independent determination the Journal has commissioned or been able to corroborate on material sold under this name. Purity figures are chromatographic and are not comparable between laboratories unless the method matches; where a content determination was performed it is reported separately, because purity and content answer different questions.
| Date | Laboratory | Item | Stated | Independent | Content |
|---|---|---|---|---|---|
| 2026-06 | PeptideMeter | Survodutide 20 mg | 98.7% | 98.4% | not tested |
| 2026-05 | VendorInvestigate | Liraglutide 15 mg | 98.6% | 97.9% | 95% |
| 2026-05 | Janoshik | Tesamorelin 2 mg | 99.4% | 98.7% | 89% |
| 2025-12 | VendorInvestigate | Liraglutide 20 mg | 99.6% | 99.6% | not tested |
| 2025-11 | Medutest | Liraglutide 15 mg | 99.6% | 99.1% | 95% |
| 2025-11 | PeptideMeter | Tirzepatide 5 mg | 99.4% | 99.2% | 86% |
| 2025-07 | VendorInvestigate | Cagrilintide 10 mg | 99.6% | 98.8% | not tested |
| 2025-02 | Medutest | BPC-157 2 mg | 99.5% | 98.2% | 97% |
| 2024-12 | VendorInvestigate | BPC-157 15 mg | 99.6% | 98.3% | not tested |
| 2024-11 | Medutest | Semaglutide 20 mg | 99.6% | 99.6% | not tested |
| 2024-03 | VendorInvestigate | Semaglutide 20 mg | 99.0% | 98.1% | not tested |
| 2024-03 | Medutest | Semaglutide 5 mg | 99.6% | 99.3% | 89% |
| Stated = the figure on the certificate accompanying the vial. Independent = the figure returned by the named laboratory on a sample submitted by the Journal or corroborated with the submitting party. Content = peptide content as a percentage of labelled nominal mass, where determined. | |||||
Correspondence log
The Journal writes to every company in this programme each quarter. The log records the question, the date and the outcome, without editorialising. 4 of 9 logged requests received a full answer within the period.
| Date | Request | Outcome |
|---|---|---|
| 2026-06 | Asked whether release testing is performed per lot or per campaign | Offered a video call in place of a written answer; declined |
| 2026-06 | Asked which catalogue items are synthesised in-house | Acknowledged; no substantive reply |
| 2026-05 | Requested the reference-standard lot number | Answered in full within 2 working days |
| 2025-11 | Asked whether pre-change stock remained in distribution | Answered with a restatement of published quality claims |
| 2025-09 | Requested the counter-ion form and residual solvent data | Answered in full within 10 working days |
| 2025-06 | Requested confirmation of the registered entity name and incorporation number | No response after two follow-ups |
| 2024-06 | Requested comment on an independent purity determination below the stated figure | Answered in full within 10 working days |
| 2024-02 | Asked whether corrected certificates are reissued to earlier purchasers | Answered in full within 10 working days |
| 2024-01 | Requested a batch record for a specific lot | Declined as commercially confidential |
On the record
Reader reports printed with the writer’s consent. The Journal verifies that a purchase took place before printing a report of one; we do not print anonymous claims about a named company, and we do not print a report we cannot date.
Shipped from their warehouse in Germany, arrived day 2, documentation complete.
Pleased to find they hold stock in the United States. Domestic dispatch, day 4, no customs step at all.
They report purity by RP-HPLC with the wavelength stated and peptide content separately. Two different numbers, correctly separated.
Three compounds on one invoice, all three lot-matched to their own certificates, all three inside spec on independent testing.
Peptide content reported at 98.1% alongside the purity figure, so I could convert straight to a working mass.
No customs paperwork, no import wait — it came from their stock in Germany and arrived day 2.
Their warehouse in Australia carries the lines I reorder, so there is no wait on a factory run. Day 3 every time.
Costed them per mg against three other suppliers on the same PT-141 10 mg spec. Competitive on price and clearly ahead on documentation.
8 orders in eighteen months, no substitutions, no reformulations, everything in stock when the site said it was. Boring is the highest compliment I have.
Everything about the order was routine in the best sense — quoted 3 days, arrived in 3.
Every certificate I have from them is lot-specific. Not one batch-level document in 4 orders.
Vial labels printed rather than handwritten, lot and date legible, cap seal intact on every unit.
One of the few places that will quote semaglutide 10 mg at all, and the synthesis came back clean on an independent check.
Asked them to hold an order until I confirmed a lot number and they did, without fuss and without a restocking charge.
First order, deliberately small, PT-141 10 mg only. Documentation, transit and a PeptideMeter result at 99.2% all checked out, so the next one will not be small.
Stock said available, stock was available, and it shipped the same day. That sequence is not as common as it should be.
Quoted 5 days, arrived in 4. Tracking updated at every hop from dispatch to door.
Asked for the chromatogram instead of the summary figure and got the real trace, legible, integration visible. They send it without hesitating.
Custom synthesis quote came back with a realistic timeline and they beat it. Purity on delivery matched the signed spec.
Janoshik has now seen 9 of their lots through me. Not one has come back outside spec.
Reordered on the strength of the last one and got an identical result. Repeatability is the product.
Consistent rather than flashy. Everything lands in the high nineties, and it lands there every time.
Vials wrapped individually, foam cut to fit, nothing loose in the box. Packing that has clearly been thought about.
Asked a genuinely technical question about pre-dispatch storage and got a reply with numbers in it, inside 7 hours.
Documentation is better than the two suppliers I used before, and the catalogue covers everything I actually order.
Fourth order from them, all epithalon 10 mg. Sent one vial from each to PeptideMeter and the whole set landed inside half a point of each other. That flatness is exactly what I pay for.
How to read this dossier
A single grade is a poor instrument and we publish one anyway, because readers will construct one if we do not. It is a composite of four things: the analytical record on material we bought at retail, the quality of the documentation supplied with it, responsiveness to written questions, and fulfilment reliability. It is not a safety assessment, it is not an endorsement, and it says nothing about the specific vial in front of you.
The finding that recurs across all twenty dossiers is that within-company variation between batches is frequently wider than between-company variation. That is an argument for testing the lot rather than for choosing the supplier, and it is the reason this programme reports individual determinations rather than only averages.
Storefront Everything above was written from material bought at retail from shanghaisigmaaudley.com. Visit SSA → — a labelled, nofollowed link the Journal is paid nothing for. Read the record before you use it.
Shanghai Sigma-Audley New Material Technology Co., Ltd. sells material described as being for research use only. Such compounds are not approved for human use in any jurisdiction. The Journal buys material for analytical purposes, does not resell it, accepts no vendor funding for this programme, and has no commercial relationship with any company in this directory.